progress with the COVID-19 vaccines programme since the NAO last reported in December 2020;
the drivers of success in the first phases of the mass roll-out: the rollout of first and second doses to all priority groups and all adults, and the rollout of first doses to 12-17 year olds
the future aims and challenges for the vaccines programme as the first phases of roll-out come to an end; and
the risks to sustainability and delivering value for money in future, including in phases yet to be evaluated such as the rollout of boosters, second doses for 12-17 year olds, and vaccines for younger children
If you have evidence on these issues please submit it here by Monday 21 March 2022.
This inquiry is no longer accepting evidence
The deadline for submissions was Monday 21 March 2022.